You have 9 free searches left this month | for more free features.

Platinum-based chemotherapy

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)

Not yet recruiting
  • Gynecologic Cancer
  • Experimental product - Fortifit® Powder
  • Standard of care
  • (no location specified)
Oct 14, 2023

Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)

Not yet recruiting
  • Cancer
  • +3 more
  • Patients suffering from chemotherapy-induced ototoxicity
  • (no location specified)
Jun 29, 2023

NSCLC Trial in Worldwide (RO7247669, Pembrolizumab, Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Benowa, Queensland, Australia
  • +6 more
Mar 16, 2023

Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Propranolol
  • Propranolol hydrochloride
  • +2 more
  • (no location specified)
Jul 31, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jun 5, 2023

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)

Recruiting
  • Toripalimab
  • First-line Treatment
  • Guangzhou, Guangdong, China
    Sun Yat-sen University cancer center
Mar 7, 2023

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Chemotherapeutic Toxicity Trial (Home Based Walking Program)

Not yet recruiting
  • Chemotherapeutic Toxicity
  • Home Based Walking Program
  • (no location specified)
Aug 28, 2023

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022

NSCLC Trial (QL1706 injection, Vinorelbine Tartrate, Paclitaxel)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • QL1706 injection
  • +6 more
  • (no location specified)
Aug 3, 2022

Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • IBI-322 Plus Lenvatinib and Platinum
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 14, 2022

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Small Cell Lung Cancer Trial in Nice (acetazolamide in combination with platinum and etoposide-based radiochemo)

Recruiting
  • Small Cell Lung Cancer
  • acetazolamide in combination with platinum and etoposide-based radiochemotherapy
  • Nice, France
    Centre Antoine Lacassagne
Jan 19, 2023

Non Small Cell Lung Cancer Trial in Changsha (Atezolizumab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 19, 2022

Pembrolizumab Combined With Double Platinum Based Chemotherapy

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Feb 28, 2022